The 36-month beta value for RPTX is at 0.85. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for RPTX is 30.77M, and currently, shorts hold a 1.65% of that float. The average trading volume for RPTX on May 15, 2025 was 313.89K shares.
RPTX) stock’s latest price update
Repare Therapeutics Inc (NASDAQ: RPTX)’s stock price has dropped by -8.74 in relation to previous closing price of 1.43. Nevertheless, the company has seen a loss of -4.04% in its stock price over the last five trading days. businesswire.com reported 2025-05-13 that CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2025. “During the first quarter of 2025 we continued our efforts to create long-term value for our shareholders via partnering and by advancing our novel pipeline programs,” said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. “W.
RPTX’s Market Performance
Repare Therapeutics Inc (RPTX) has experienced a -4.04% fall in stock performance for the past week, with a 40.59% rise in the past month, and a 13.48% rise in the past quarter. The volatility ratio for the week is 7.06%, and the volatility levels for the past 30 days are at 9.11% for RPTX. The simple moving average for the past 20 days is -1.79% for RPTX’s stock, with a -41.01% simple moving average for the past 200 days.
Analysts’ Opinion of RPTX
Many brokerage firms have already submitted their reports for RPTX stocks, with Stifel repeating the rating for RPTX by listing it as a “Buy.” The predicted price for RPTX in the upcoming period, according to Stifel is $16 based on the research report published on June 09, 2023 of the previous year 2023.
Morgan Stanley, on the other hand, stated in their research note that they expect to see RPTX reach a price target of $15, previously predicting the price at $28. The rating they have provided for RPTX stocks is “Equal-Weight” according to the report published on February 03rd, 2023.
CapitalOne gave a rating of “Overweight” to RPTX, setting the target price at $28 in the report published on January 06th of the previous year.
RPTX Trading at 11.58% from the 50-Day Moving Average
After a stumble in the market that brought RPTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.58% of loss for the given period.
Volatility was left at 9.11%, however, over the last 30 days, the volatility rate increased by 7.06%, as shares surge +18.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.54% upper at present.
During the last 5 trading sessions, RPTX fell by -4.04%, which changed the moving average for the period of 200-days by -66.88% in comparison to the 20-day moving average, which settled at $1.3288. In addition, Repare Therapeutics Inc saw -0.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RPTX starting from Koehler Maria, who sale 3,596 shares at the price of $1.14 back on Mar 12 ’25. After this action, Koehler Maria now owns 227,813 shares of Repare Therapeutics Inc, valued at $4,099 using the latest closing price.
Zinda Michael, the EVP, CHIEF SCIENTIFIC OFFICER of Repare Therapeutics Inc, sale 5,611 shares at $1.14 during a trade that took place back on Mar 12 ’25, which means that Zinda Michael is holding 80,297 shares at $6,397 based on the most recent closing price.
Stock Fundamentals for RPTX
Current profitability levels for the company are sitting at:
- -1.74 for the present operating margin
- 0.98 for the gross margin
The net margin for Repare Therapeutics Inc stands at -1.58. The total capital return value is set at -0.62. Equity return is now at value -71.64, with -62.83 for asset returns.
Based on Repare Therapeutics Inc (RPTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -39.55.
Currently, EBITDA for the company is -93.52 million with net debt to EBITDA at 0.92. When we switch over and look at the enterprise to sales, we see a ratio of -0.5. The receivables turnover for the company is 4.33for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.42.
Conclusion
In conclusion, Repare Therapeutics Inc (RPTX) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
